
Three questions about the latest study on statin deprescribing
At the recent American Heart Association annual meeting, the main theme dominating the stage, bathed in Pantone red, was one of the most high-profile neutral discoveries.
Listening to the results of the STREAM trial — which found that older people without a history of heart attack or stroke who stopped taking statins did not have significantly different outcomes than those who continued taking them — I noted that the study continued the theme.
But as the Kaplan-Meier curves were projected onto the screen, something was wrong: the curves were diverging instead of staying together. Theoretically, this scenario can occur in non-inferiority studies, in which researchers test whether an intervention offers similar results compared to a standard. Statin deprescription in this group, according to the expectations set by researchers at the start of STREAM, was technically noninferior, but nonetheless inferior. Patients randomized to stop taking their statin had worse outcomes than those who continued. Even the trial’s data safety monitoring board suggested that patients who have stopped taking statins should talk to their doctors about restarting their treatment.

This article is reserved for STAT+ subscribers
Unlock this article, plus in-depth analysis, newsletters, premium events and news alerts.
Already have an account? Log in
See all packages
Gn Health